E.I. Eboulet

611 total citations
15 papers, 171 citations indexed

About

E.I. Eboulet is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, E.I. Eboulet has authored 15 papers receiving a total of 171 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in E.I. Eboulet's work include Lung Cancer Diagnosis and Treatment (5 papers), Radiomics and Machine Learning in Medical Imaging (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). E.I. Eboulet is often cited by papers focused on Lung Cancer Diagnosis and Treatment (5 papers), Radiomics and Machine Learning in Medical Imaging (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). E.I. Eboulet collaborates with scholars based in Switzerland, Germany and Italy. E.I. Eboulet's co-authors include Miklos Pless, Michael Mark, Solange Peters, Patrizia Froesch, Sandra Thierstein, Matthias Gückenberger, Diem Vuong, Stephanie Tanadini‐Lang, Marta Bogowicz and Martin Früh and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

E.I. Eboulet

14 papers receiving 170 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.I. Eboulet Switzerland 9 125 76 59 21 16 15 171
Lorenzo Vinante Italy 7 59 0.5× 43 0.6× 100 1.7× 11 0.5× 10 0.6× 19 181
J.A. Messer United States 6 67 0.5× 52 0.7× 64 1.1× 8 0.4× 7 0.4× 17 164
Tuğçe Kütük United States 8 112 0.9× 42 0.6× 34 0.6× 14 0.7× 30 1.9× 42 167
Erik V. Soloff United States 8 69 0.6× 154 2.0× 100 1.7× 30 1.4× 22 1.4× 21 204
Vanessa Moreno United States 8 129 1.0× 27 0.4× 63 1.1× 10 0.5× 6 0.4× 25 235
Anne-Maree Haynes Australia 6 221 1.8× 23 0.3× 115 1.9× 17 0.8× 6 0.4× 6 265
Marika Reinius United Kingdom 6 38 0.3× 46 0.6× 80 1.4× 36 1.7× 5 0.3× 11 192
Qing Bi China 7 49 0.4× 63 0.8× 34 0.6× 7 0.3× 16 1.0× 8 148
Anas Alshawa United States 6 57 0.5× 126 1.7× 63 1.1× 21 1.0× 26 1.6× 11 232
G.A. Jiménez Londoño Spain 9 102 0.8× 27 0.4× 156 2.6× 17 0.8× 5 0.3× 39 248

Countries citing papers authored by E.I. Eboulet

Since Specialization
Citations

This map shows the geographic impact of E.I. Eboulet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.I. Eboulet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.I. Eboulet more than expected).

Fields of papers citing papers by E.I. Eboulet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.I. Eboulet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.I. Eboulet. The network helps show where E.I. Eboulet may publish in the future.

Co-authorship network of co-authors of E.I. Eboulet

This figure shows the co-authorship network connecting the top 25 collaborators of E.I. Eboulet. A scholar is included among the top collaborators of E.I. Eboulet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.I. Eboulet. E.I. Eboulet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Panje, Cédric, Stefanie Hayoz, Wolfgang Eisterer, et al.. (2022). Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. European Journal of Cancer. 177. 186–193. 2 indexed citations
2.
Furrer, Katarzyna, Walter Weder, E.I. Eboulet, et al.. (2022). Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment. Journal of Thoracic and Cardiovascular Surgery. 164(6). 1587–1602.e5. 8 indexed citations
3.
Vuong, Diem, Marta Bogowicz, Martin Hüllner, et al.. (2021). Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. EJNMMI Research. 11(1). 79–79. 12 indexed citations
4.
Vuong, Diem, Marta Bogowicz, Leonard Wee, et al.. (2021). Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. Scientific Reports. 11(1). 20890–20890. 5 indexed citations
5.
Addeo, Alfredo, Markus Joerger, Sacha I. Rothschild, et al.. (2021). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.. Journal of Clinical Oncology. 39(15_suppl). e21119–e21119. 4 indexed citations
6.
Alborelli, Ilaria, Katharina Leonards, E. Keller, et al.. (2021). MA09.02 SAKK 16/14 - T-Cell Receptor Repertoire Metrics Predict Response to Neoadjuvant Durvalumab in Patients With Stage IIIA(N2) NSCLC. Journal of Thoracic Oncology. 16(10). S911–S911. 3 indexed citations
7.
Vuong, Diem, Marta Bogowicz, Matea Pavic, et al.. (2021). Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types. British Journal of Radiology. 94(1120). 20200947–20200947. 23 indexed citations
8.
9.
Vees, Hansjörg, Francesca Caparrotti, E.I. Eboulet, et al.. (2020). Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12). International Journal of Radiation Oncology*Biology*Physics. 107(2). 279–287. 25 indexed citations
10.
Vuong, Diem, Stephanie Tanadini‐Lang, Robert J. Marks, et al.. (2020). Radiomics Feature Activation Maps as a New Tool for Signature Interpretability. Frontiers in Oncology. 10. 578895–578895. 19 indexed citations
11.
Rothschild, Sacha I., Alfred Zippelius, E.I. Eboulet, et al.. (2020). SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.. Journal of Clinical Oncology. 38(15_suppl). 9016–9016. 24 indexed citations
12.
Mark, Michael, Patrizia Froesch, E.I. Eboulet, et al.. (2020). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunology Immunotherapy. 70(5). 1255–1262. 11 indexed citations
13.
Metaxas, Yannis, Martin Früh, E.I. Eboulet, et al.. (2020). Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). Annals of Oncology. 31(4). 495–500. 22 indexed citations
14.
Metaxas, Yannis, M. Frueh, E.I. Eboulet, et al.. (2019). SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial. Annals of Oncology. 30. v748–v748. 2 indexed citations
15.
Eboulet, E.I., et al.. (2013). Application de la régression quantile et ses tests statistiques sur les données PISA en Suisse romande.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lorenzo Vinante Breakdown of academic impact, for papers by J.A. Messer Breakdown of academic impact, for papers by Tuğçe Kütük Breakdown of academic impact, for papers by Erik V. Soloff Breakdown of academic impact, for papers by Vanessa Moreno Breakdown of academic impact, for papers by Anne-Maree Haynes Breakdown of academic impact, for papers by Marika Reinius Breakdown of academic impact, for papers by Qing Bi Breakdown of academic impact, for papers by Anas Alshawa Breakdown of academic impact, for papers by G.A. Jiménez Londoño
Rankless by CCL
2026